WO2007047609A2 - INHIBITION OF PLACENTA GROWTH FACTOR (PlGF) MEDICATED METASTASIS AND/OR ANGIOGENESIS - Google Patents

INHIBITION OF PLACENTA GROWTH FACTOR (PlGF) MEDICATED METASTASIS AND/OR ANGIOGENESIS Download PDF

Info

Publication number
WO2007047609A2
WO2007047609A2 PCT/US2006/040431 US2006040431W WO2007047609A2 WO 2007047609 A2 WO2007047609 A2 WO 2007047609A2 US 2006040431 W US2006040431 W US 2006040431W WO 2007047609 A2 WO2007047609 A2 WO 2007047609A2
Authority
WO
WIPO (PCT)
Prior art keywords
ligand
antibody
plgf
composition
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/040431
Other languages
English (en)
French (fr)
Other versions
WO2007047609A3 (en
Inventor
David M. Goldenberg
Chien Hsing Chang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunomedics Inc
Center for Molecular Medicine and Immunology
Original Assignee
Immunomedics Inc
Center for Molecular Medicine and Immunology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunomedics Inc, Center for Molecular Medicine and Immunology filed Critical Immunomedics Inc
Priority to JP2008536725A priority Critical patent/JP5498018B2/ja
Priority to EP06826058A priority patent/EP1937724A4/en
Priority to CA2625992A priority patent/CA2625992C/en
Priority to KR1020087009357A priority patent/KR101287280B1/ko
Priority to AU2006304418A priority patent/AU2006304418B2/en
Publication of WO2007047609A2 publication Critical patent/WO2007047609A2/en
Anticipated expiration legal-status Critical
Publication of WO2007047609A3 publication Critical patent/WO2007047609A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Microbiology (AREA)
PCT/US2006/040431 2005-10-19 2006-10-16 INHIBITION OF PLACENTA GROWTH FACTOR (PlGF) MEDICATED METASTASIS AND/OR ANGIOGENESIS Ceased WO2007047609A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2008536725A JP5498018B2 (ja) 2005-10-19 2006-10-16 胎盤成長因子（ＰｌＧＦ）媒介性の転移および／または血管新生の阻害
EP06826058A EP1937724A4 (en) 2005-10-19 2006-10-16 INHIBITION OF PLAZENTA GROWTH FACTOR INDUCED METASTASES AND / OR ANGIOGENESIS
CA2625992A CA2625992C (en) 2005-10-19 2006-10-16 Inhibition of placenta growth factor (p1gf) mediated metastasis and/or angiogenesis
KR1020087009357A KR101287280B1 (ko) 2005-10-19 2006-10-16 태반 성장 인자 매개된 전이 및/또는 혈관신생의 억제
AU2006304418A AU2006304418B2 (en) 2005-10-19 2006-10-16 Inhibition of placenta growth factor (PIGF) mediated metastasis and/or angiogenesis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72829205P 2005-10-19 2005-10-19
US60/728,292 2005-10-19

Publications (2)

Publication Number Publication Date
WO2007047609A2 true WO2007047609A2 (en) 2007-04-26
WO2007047609A3 WO2007047609A3 (en) 2009-03-19

Family

ID=37963183

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/040431 Ceased WO2007047609A2 (en) 2005-10-19 2006-10-16 INHIBITION OF PLACENTA GROWTH FACTOR (PlGF) MEDICATED METASTASIS AND/OR ANGIOGENESIS

Country Status (8)

Country Link
US (3) US7642239B2 (https=)
EP (1) EP1937724A4 (https=)
JP (1) JP5498018B2 (https=)
KR (1) KR101287280B1 (https=)
CN (2) CN101534865A (https=)
AU (1) AU2006304418B2 (https=)
CA (1) CA2625992C (https=)
WO (1) WO2007047609A2 (https=)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010037864A3 (en) * 2008-10-02 2010-07-01 Vib Vzw Inhibition of plgf to treat philadelphia chromosome positive leukemia
US7878978B2 (en) 2004-03-18 2011-02-01 University Of Pittsburgh- Of The Commonwealth System Of Higher Education Use of relaxin to increase arterial compliance
CN102015768A (zh) * 2008-05-08 2011-04-13 拜耳先灵医药股份有限公司 与ed-b纤连蛋白特异性结合的放射性标记分子在治疗霍奇金淋巴瘤的方法中的用途
US8865857B2 (en) 2010-07-01 2014-10-21 Sofradim Production Medical device with predefined activated cellular integration
US9089552B2 (en) 2011-12-01 2015-07-28 Thrombogenics Nv Improving trabeculectomy outcome by administering an anti-placental growth factor antibody
US9247931B2 (en) 2010-06-29 2016-02-02 Covidien Lp Microwave-powered reactor and method for in situ forming implants
US9510810B2 (en) 2009-02-21 2016-12-06 Sofradim Production Medical devices incorporating functional adhesives
US9775928B2 (en) 2013-06-18 2017-10-03 Covidien Lp Adhesive barbed filament
WO2017185662A1 (zh) * 2016-04-29 2017-11-02 深圳市中联生物科技开发有限公司 多特异性结合偶联物、相关的药物组合物及应用
US11000603B2 (en) 2015-04-14 2021-05-11 Benhealth Biopharmaceutic (Shenzhen) Co., Ltd. Multi-specific binding conjugate, related pharmaceutical compositions and use
US11525009B2 (en) 2016-06-22 2022-12-13 Benhealth Biopharmaceutic (Shenzhen) Co. Ltd. Bispecific antibody and antibody conjugate for tumor therapy and use thereof

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7591994B2 (en) 2002-12-13 2009-09-22 Immunomedics, Inc. Camptothecin-binding moiety conjugates
US8067006B2 (en) * 2005-04-06 2011-11-29 Immunomedics, Inc. Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites
US8021646B2 (en) * 2006-12-08 2011-09-20 Northwestern University Compositions and methods for magnetic resonance imaging contrast agents
WO2008151021A1 (en) * 2007-06-01 2008-12-11 Nevada Cancer Institute Isolation and growth of stem cells from hemangiomas
US20080299077A1 (en) * 2007-06-01 2008-12-04 Nevada Cancer Institute Isolation and growth of stem cells from hemangiomas
WO2009080764A2 (en) * 2007-12-20 2009-07-02 Abylnx N.V. Oral or nasal administration of compounds comprising amino acid sequences
US8034396B2 (en) * 2008-04-01 2011-10-11 Tyco Healthcare Group Lp Bioadhesive composition formed using click chemistry
JP2011520902A (ja) * 2008-05-16 2011-07-21 コーセラ，インコーポレーテッド 創傷の治癒を促進する方法
US8741287B2 (en) * 2008-06-18 2014-06-03 Abbott Laboratories PlGF-1 assay and kits and components thereof
US20100004306A1 (en) * 2008-06-18 2010-01-07 Abbott Laboratories PIGF-1 Assay and kits and components thereof
JP2011525241A (ja) * 2008-06-18 2011-09-15 アボット・ラボラトリーズ ＰｌＧＦ−１コンパニオン診断方法および製品
US8940331B2 (en) * 2008-11-22 2015-01-27 The Board Of Trustees Of The Leland Stanford Junior University Hydrogels, methods of making hydrogels, methods of using hydrogels, and methods of isolating, trapping, attracting, and/or killing cancer cells
AU2009329994B2 (en) * 2008-12-23 2014-04-03 Genentech, Inc. Methods and compositions for diagnostic use in cancer patients
EP3912643B8 (en) 2009-02-13 2023-08-23 Immunomedics, Inc. Immunoconjugates with an intracellularly-cleavable linkage
US8968733B2 (en) * 2009-02-21 2015-03-03 Sofradim Production Functionalized surgical adhesives
EP2398584A2 (en) 2009-02-21 2011-12-28 Sofradim Production Apparatus and method of reaching polymers by exposure to uv radiation to produce injectable medical devices
US8877170B2 (en) * 2009-02-21 2014-11-04 Sofradim Production Medical device with inflammatory response-reducing coating
EP2398519A2 (en) 2009-02-21 2011-12-28 Sofradim Production Compounds and medical devices activated with solvophobic linkers
WO2010095045A1 (en) 2009-02-21 2010-08-26 Sofradim Production Amphiphilic compounds and self-assembling compositions made therefrom
EP2398524B1 (en) 2009-02-21 2017-07-12 Covidien LP Medical devices having activated surfaces
US9039979B2 (en) 2009-02-21 2015-05-26 Sofradim Production Apparatus and method of reacting polymers passing through metal ion chelated resin matrix to produce injectable medical devices
US8512728B2 (en) 2009-02-21 2013-08-20 Sofradim Production Method of forming a medical device on biological tissue
US8663689B2 (en) * 2009-02-21 2014-03-04 Sofradim Production Functionalized adhesive medical gel
WO2010095049A1 (en) 2009-02-21 2010-08-26 Sofradim Production Crosslinked fibers and method of making same by extrusion
CA2753188A1 (en) 2009-02-21 2010-08-26 Tyco Healthcare Group Lp Medical devices having activated surfaces
US9523159B2 (en) 2009-02-21 2016-12-20 Covidien Lp Crosslinked fibers and method of making same using UV radiation
WO2010095056A2 (en) 2009-02-21 2010-08-26 Sofradim Production Medical devices with an activated coating
WO2010097800A1 (en) * 2009-02-26 2010-09-02 Muhammad Abdulrazik Synergistic combination of bioactive compounds for lowering of intraocular pressure
ES2978177T3 (es) 2009-12-02 2024-09-06 Immunomedics Inc Combinación de radio inmunoterapia y conjugados anticuerpo-fármaco para mejorar la terapia contra el cáncer
US20120259099A1 (en) * 2009-12-15 2012-10-11 MuHyeon CHOE Method for manufacturing dimers and multimers by increasing the production of bond bridges in a complex of multiple monomers and repeating chains of an adherend of a type specifically adhering to monomers
IL205774A0 (en) * 2010-05-13 2010-12-30 Muhammad Abdulrazik Novel compounds for the treatment of glaucoma and ocular hypertension
AU2011231245B2 (en) 2010-03-25 2015-03-26 Covidien Lp Medical devices incorporating functional adhesives
CA2794336A1 (en) * 2010-03-25 2011-09-29 Sofradim Production Surgical fasteners and methods for sealing wounds
CN102971422B (zh) * 2010-07-02 2015-07-22 国立大学法人东京农工大学 Psa结合适体和前列腺癌的诊断方法
EP2598178B1 (en) 2010-07-27 2018-07-11 Sofradim Production Polymeric fibers having tissue reactive members
CN102028955A (zh) * 2010-08-09 2011-04-27 华中科技大学同济医学院附属同济医院 一种用于肿瘤基因干预的新型靶向复合物
CN102680619A (zh) * 2011-03-09 2012-09-19 北京康华源医药信息咨询有限公司 一种胶体金属定量检测技术及其用途
AU2012250924B2 (en) 2011-05-02 2017-05-25 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
CN102286101B (zh) * 2011-08-08 2013-05-08 常州亚当生物技术有限公司 抗VEGF单克隆抗体Fab片段Vasculizumab及其应用
WO2013032853A1 (en) 2011-08-26 2013-03-07 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Activators of cxcr3 for the treatment of angiopathies of the eye
CN102505180A (zh) * 2011-09-16 2012-06-20 彭可扬 一种用于防治室内微生物污染的负载伊曲康唑-溶菌酶电纺纤维膜
CN103087196B (zh) * 2012-06-26 2016-12-21 青岛大学附属医院 胞壁酰二肽-抗cd20免疫偶联物制备方法及应用
AU2013302696B9 (en) 2012-08-14 2018-08-09 Ibc Pharmaceuticals, Inc. T-cell redirecting bispecific antibodies for treatment of disease
SI2900277T1 (sl) * 2012-12-13 2022-05-31 Immunomedics, Inc. Odmerki imunokonjugatov protiteles in SN-38 za boljšo učinkovitost in zmanjšano toksičnost
EP3094336A4 (en) 2014-01-17 2018-02-14 MIMEDX Group Inc. Method for inducing angiogenesis
US9895419B2 (en) 2014-01-21 2018-02-20 University of Pittsburgh—of the Commonwealth System of Higher Education Goblet cell replacement therapy
WO2015126548A1 (en) 2014-02-21 2015-08-27 Ibc Pharmaceuticals, Inc. Disease therapy by inducing immune response to trop-2 expressing cells
US9139649B2 (en) 2014-02-25 2015-09-22 Immunomedics, Inc. Humanized anti-CD22 antibody
CN104109670B (zh) * 2014-03-12 2018-01-05 首都医科大学附属北京安定医院 一种双链siRNA分子及其应用
TWI625123B (zh) 2014-03-31 2018-06-01 分離胎盤中雌激素之方法
WO2015200260A1 (en) 2014-06-24 2015-12-30 Immunomedics, Inc. Anti-histone therapy for vascular necrosis in severe glomerulonephritis
CN117138060A (zh) 2014-10-07 2023-12-01 免疫医疗公司 抗体-药物缀合物的新辅助剂用途
KR101551306B1 (ko) * 2015-03-23 2015-09-09 아주대학교산학협력단 뉴로필린1 특이적 결합 펩타이드 및 이 펩타이드가 융합된 융합 단백질, 및 이의 용도
WO2016172427A1 (en) 2015-04-22 2016-10-27 Immunomedics, Inc. Isolation, detection, diagnosis and/or characterization of circulating trop-2-positive cancer cells
EP4257134A3 (en) 2015-06-25 2024-01-24 Immunomedics, Inc. Combining anti-hla-dr or anti-trop-2 antibodies with microtubule inhibitors, parp inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
PL3316885T3 (pl) 2015-07-01 2021-12-06 Immunomedics, Inc. Immunokoniugaty przeciwciało-sn-38 z linkerem cl2a
CN105669871A (zh) * 2016-04-19 2016-06-15 中国药科大学 一种胸腺肽α1的融合蛋白
CN107362370B (zh) * 2016-05-13 2022-07-26 国家纳米科学中心 一种基于金纳米簇联合NGF siRNA治疗胰腺癌的方法
CN106596911B (zh) * 2016-12-16 2019-07-19 石河子大学 一种证明缝隙连接在高血压炎症反应中的作用的试验方法
CN110382550A (zh) 2017-01-24 2019-10-25 本康生物制药（深圳）有限公司 抗体偶联物、相关的药物组合物及应用
JP7560357B2 (ja) * 2017-11-22 2024-10-02 フイルメニツヒ ソシエテ アノニム ランドリーの悪臭、カビの悪臭及び／又は汗の悪臭を調節する組成物を同定する方法
CN110326584B (zh) * 2019-07-04 2020-06-19 西安交通大学 一种p物质诱导的过敏性哮喘动物模型的构建方法和筛选药物的方法
EP4178624A2 (en) 2020-07-07 2023-05-17 Bionecure Therapeutics, Inc. Maytansinoids as adc payloads and their use for the treatment of cancer
US20250073349A1 (en) 2021-05-10 2025-03-06 Kawasaki Institute Of Industrial Promotion Antibody having reduced binding affinity for antigen
CN114404367B (zh) * 2021-12-29 2023-02-21 中山大学附属第一医院 一种通过对病变细胞靶向分布的纳米载体及其制备方法和应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5686578A (en) * 1994-08-05 1997-11-11 Immunomedics, Inc. Polyspecific immunoconjugates and antibody composites for targeting the multidrug resistant phenotype
US5874540A (en) * 1994-10-05 1999-02-23 Immunomedics, Inc. CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies
GB9723780D0 (en) 1997-11-12 1998-01-07 Univ Manchester Regulation of ocular angiogenesis
US20040053837A1 (en) 1998-09-30 2004-03-18 Ludwig Institute For Cancer Research Composition and method for modulating vasculogenesis or angiogenesis
EP1179541B1 (en) * 1999-04-28 2004-06-16 Board Of Regents, The University Of Texas System Compositions and methods for cancer treatment by selectively inhibiting VEGF
US7105168B1 (en) 2002-06-04 2006-09-12 D. Collen Research Foundation Vzw Method of improving ischemic muscle function by administering placental growth factor
US6930089B2 (en) 2000-02-04 2005-08-16 D. Collen Research Foundation Vzw Use of vascular endothelial growth factor, placenta growth factor or both for preventing or treating ischemic disease or stroke
US7727971B2 (en) 2000-02-04 2010-06-01 Life Sciences Research Partners Vzw Use of placental growth factor for treating ischemic muscle disease
DK2277528T3 (en) 2000-04-12 2015-01-26 Vib Vzw Use of VEGF and homologs for treatment of neuronal diseases
CA2407858C (en) * 2000-05-12 2015-10-27 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Use of inhibitors of placental growth factor for the treatment of pathological angiogenesis, pathological arteriogenesis, inflammation, tumour formation and/or vascular leakage
AU2002241801A1 (en) * 2000-11-07 2002-06-18 Gpc Biotech Inc. Methods and reagents for isolating angiogenic modulators
US20050043227A1 (en) 2001-04-24 2005-02-24 Veerle Compernolle Use of hypoxia inducible factor 2alpha for curing neonatal respiratory distress syndrome and as a target for the treatment of pulmonary hypertension
JP2003012541A (ja) * 2001-06-07 2003-01-15 Daiichi Fine Chemical Co Ltd 血管新生阻害剤
AU2003251728A1 (en) 2002-06-28 2004-01-19 K.U.Leuven Research & Development Placental growth factor as a target for the treatment of osteoporosis
ATE555133T1 (de) * 2003-11-13 2012-05-15 Hanmi Holdings Co Ltd Igg fc fragment für einen arzneimittelträger und verfahren zu dessen herstellung
EP2447281B1 (en) * 2005-03-24 2015-12-16 ThromboGenics N.V. Novel anti-PLGF antibody

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of EP1937724A4 *

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8602998B2 (en) 2004-03-18 2013-12-10 University of Pittsburgh—of the Commonwealth System of Higher Education Use of relaxin to increase arterial compliance
US7878978B2 (en) 2004-03-18 2011-02-01 University Of Pittsburgh- Of The Commonwealth System Of Higher Education Use of relaxin to increase arterial compliance
CN102015768A (zh) * 2008-05-08 2011-04-13 拜耳先灵医药股份有限公司 与ed-b纤连蛋白特异性结合的放射性标记分子在治疗霍奇金淋巴瘤的方法中的用途
US10106601B2 (en) 2008-10-02 2018-10-23 Vib Vzw Inhibition of PLGF to treat philadelphia chromosome positive leukemia
JP2012504583A (ja) * 2008-10-02 2012-02-23 ヴェーイーベー ヴェーゼットウェー フィラデルフィア染色体陽性白血病を治療するためのＰｌＧＦの阻害
KR101798664B1 (ko) * 2008-10-02 2017-11-16 브이아이비 브이지더블유 필라델피아 염색체 양성 백혈병의 치료를 위한 피엘지에프의 억제
WO2010037864A3 (en) * 2008-10-02 2010-07-01 Vib Vzw Inhibition of plgf to treat philadelphia chromosome positive leukemia
US9510810B2 (en) 2009-02-21 2016-12-06 Sofradim Production Medical devices incorporating functional adhesives
US9247931B2 (en) 2010-06-29 2016-02-02 Covidien Lp Microwave-powered reactor and method for in situ forming implants
US8865857B2 (en) 2010-07-01 2014-10-21 Sofradim Production Medical device with predefined activated cellular integration
US9089552B2 (en) 2011-12-01 2015-07-28 Thrombogenics Nv Improving trabeculectomy outcome by administering an anti-placental growth factor antibody
US9775928B2 (en) 2013-06-18 2017-10-03 Covidien Lp Adhesive barbed filament
US11000603B2 (en) 2015-04-14 2021-05-11 Benhealth Biopharmaceutic (Shenzhen) Co., Ltd. Multi-specific binding conjugate, related pharmaceutical compositions and use
WO2017185662A1 (zh) * 2016-04-29 2017-11-02 深圳市中联生物科技开发有限公司 多特异性结合偶联物、相关的药物组合物及应用
CN109195992A (zh) * 2016-04-29 2019-01-11 本康生物制药（深圳）有限公司 多特异性结合偶联物、相关的药物组合物及应用
US11525009B2 (en) 2016-06-22 2022-12-13 Benhealth Biopharmaceutic (Shenzhen) Co. Ltd. Bispecific antibody and antibody conjugate for tumor therapy and use thereof

Also Published As

Publication number Publication date
AU2006304418A1 (en) 2007-04-26
WO2007047609A3 (en) 2009-03-19
CN101534849A (zh) 2009-09-16
US20110189268A1 (en) 2011-08-04
AU2006304418B2 (en) 2013-03-28
US20070087001A1 (en) 2007-04-19
JP2009514813A (ja) 2009-04-09
KR101287280B1 (ko) 2013-07-23
CN101534865A (zh) 2009-09-16
EP1937724A2 (en) 2008-07-02
US7932212B2 (en) 2011-04-26
EP1937724A4 (en) 2009-11-04
KR20080055932A (ko) 2008-06-19
CA2625992A1 (en) 2007-04-26
CA2625992C (en) 2014-05-27
US7642239B2 (en) 2010-01-05
JP5498018B2 (ja) 2014-05-21
US20100216662A1 (en) 2010-08-26

Similar Documents

Publication Publication Date Title
WO2007047609A2 (en) INHIBITION OF PLACENTA GROWTH FACTOR (PlGF) MEDICATED METASTASIS AND/OR ANGIOGENESIS
JP2009514813A5 (https=)
JP7607498B2 (ja) 成長分化因子１５（ｇｄｆ－１５）に対するモノクローナル抗体およびがん悪液質およびがんを処置するためのその使用
US9683045B2 (en) Biological materials related to c-Met
TWI443109B (zh) 抗ｅｐｈａ２抗體
CN102421802B (zh) 人源化的axl抗体
CN104853775B (zh) 针对生长和分化因子15(gdf-15)的单克隆抗体
JP2022513053A (ja) Ｂ７－Ｈ３のＩｇＶドメインに対するモノクローナル抗体及びその使用
JP2010518820A5 (https=)
US9346884B2 (en) Biological materials related to c-Met
CN105452292A (zh) 使用结合细胞表面grp78的抗体进行癌症治疗
CN103261225A (zh) 作为用于抑制病理性血管生成和肿瘤细胞侵袭力的治疗剂以及用于分子成像和靶向递送的抗DEspR抑制剂
JP2011504176A (ja) マクロファージ刺激タンパク質受容体（ｒｏｎ）の阻害およびその処置の方法
EA017995B1 (ru) Антиген, связанный с вариантами рака легкого и лимфомами
JP7720989B2 (ja) Ｅｇｆｒ及びｈｅｒ３を標的とする二重特異性四価抗体
WO2023071676A1 (zh) 一种抗her2/抗pd-l1双功能抗体及其应用
JP6491642B2 (ja) ｍＡｂ２抗Ｍｅｔ抗体
JP2005515967A5 (https=)
EP2714742A1 (en) Magea3 binding antibodies
CN118139884A (zh) 人源化抗clec-1a抗体和其抗原结合片段及其模拟物
TW202540198A (zh) 雙特異性抗體樣蛋白以及彼之製造及使用方法
TW202540199A (zh) 靶向her2及her3之雙特異性四價抗體
AU2013201446B2 (en) Biological materials related to c-Met
AU2024340685A1 (en) Her3/met binding molecule and pharmaceutical use thereof
Rader Monoclonal antibody therapy for cancer

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200680039268.X

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006826058

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2006304418

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2625992

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2008536725

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020087009357

Country of ref document: KR

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 3448/DELNP/2008

Country of ref document: IN